Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis. Federal Guidelines

This article contains clinical guidelines and current approaches to diagnosis and treatment of idiopathic pulmonary fibrosis (IPF). The aims of development this guidelines were to improve early detection and efficacy of pharmacological and non-pharmacological therapy of IPF. Achieving these goals indicates improvement in medical care quality for these patients. These guidelines are intended to pulmonologists, therapeutists and other medical specialists, healthcare managers and other healthcare providers

1. Raghu G., Collard H.R., Egan J.J. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis; evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788–824.

2. Raghu G., Rochwerg B., Zhang Y. et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: executive summary an update of the 2011 clinical practice guideline. Am. J. Respir. Crit. Care Med. 2015; 192: e3–e19.

3. Travis W.D., Costabe U., Hansell D.M.et al. An official American Thoracic Society / European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013; 188: 733–748.

4. Ryu J.H., Moua T., Daniels C.E. et al. Idiopathic pulmonary fibrosis: evolving concepts. Mayo. Clin. Proc. 2014; 89: 1130–1142.

5. Taskar V.S., Coultas D.B. Is idiopathic pulmonary fibrosis an environmental disease. Proc. Am. Thorac. Soc. 2006; 3: 293–298.

6. El-Serag H.B., Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology. 1997; 113: 755–760.

7. Lee J.S., Song J.W., Wolters P.J. et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur. Respir. J. 2012; 39: 352–358.

8. Garcıa-Sancho Figueroa M.C., Carrillo G., Perez-Padilla R. et al. Risk factors for idiopathic pulmonary fibrosis in a Mexican population. A case-control study. Respir. Med. 2010; 104: 305–309.

9. Wolters P.J., Collard H.R., Jones K.D. Pathogenesis of idiopathic pulmonary fibrosis. Ann. Rev. Pathol. 2014; 9: 157–179.

10. Hodgson U., Pulkkinen V., Dixon M. et al. ELMOD2 is a candidate gene for familial idiopathic pulmonary fibrosis. Am. J. Hum. Genet. 2006; 79: 149–154.

11. Raghu G., Weycker D., Edelsberg J. et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2006; 174: 810–816.

12. Coultas D.B., Zumwalt R.E., Black W.C., Sobonya R.E. The epidemiology of interstitial lung diseases. Am. J. Respir. Crit. Care Med. 1994; 150: 967–972.

13. Nalysnyk L., Cid-Ruzafa J., Rotella P. et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur. Respir. Rev. 2012; 21: 355–361.

14. Richeldi L., Rubin A.S., Avdeev S. et al. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Med. 2015; 13: 237.

15. Johnston I.D.A., Prescott R.J., Chalmers J.C. et al. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Thorax. 1997; 52: 38–44.

16. du Bois R.M., Wells A.U. Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis. Eur. Respir. J. 2001; 18 (Suppl. 32): 43s–55s.

17. Piirila P., Sovijarvi A.R.A. Crackles: recording, analysis and clinical significance. Eur. Respir. J. 1995; 8: 2139–2148.

18. Flaherty K.R., King T.E. Jr, Raghu G. et al. Idiopathic interstitial pneumonia: what is the effect of a ultidisciplinary approach to diagnosis? Am. J. Respir. Crit. Care Med. 2004; 170: 904–910.

19. Monaghan H., Wells A.U., Colby T.V. et al. Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest. 2004; 125: 522–526.

20. Flaherty K.R., Travis W.D., Colby T.V. et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2001; 164: 1722–1727.

21. Miller J.D., Urschel J.D., Cox G. et al. A randomized, controlled trial comparing thoracoscopy and limited thoracotomy for lung biopsy in interstitial lung disease. Ann. Thorac. Surg. 2000; 70: 1647–1650.

22. Carnochan F.M., Walker W.S., Cameron E.W. Efficacy of video assisted thoracoscopic lung biopsy: an historical comparison with open lung biopsy. Thorax. 1994; 49: 361–363.

23. Leslie K.O., Gruden J.F., Parish J.M., Scholand M.B. Transbronchial biopsy interpretation in the patient with diffuse parenchymal lung disease. Arch. Pathol. Lab. Med. 2007; 131: 407–423.

24. Grenier P., Valeyre D., Cluzel P. et al. Chronic diffuse interstitial lung disease: diagnostic value of chest radiography and high-resolution CT. Radiology. 1991; 179: 123–132.

25. Hansell D.M., Bankier A.A., MacMahon H. et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008; 246: 697–722.

26. Johkoh T., Sakai F., Noma S. et al. Honeycombing on CT: its definitions, pathologic correlation, and future directionof its diagnosis. Eur. J. Radiol. 2014; 83: 27–31.

27. Sverzellati N., Wells A.U., Tomassetti S. et al. Biopsy-proved idiopathic pulmonary fibrosis: spectrum of nondiagnostic thin-section CT diagnoses. Radiology. 2010; 254: 957–964.

28. Behr J., Kreuter M., Hoeper M.M. et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur. Respir. J. 2015; 46: 186–196.

29. Wiggins J., Strickland B., Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir. Med. 1990. 84: 365–369.

30. Doherty M.J., Pearson M.G., O’Grady E.A. et al. Cryptogenic fibrosing alveolitis with preserved lung volumes. Thorax. 1997. 52: 998–1002.

31. Collard H.R., King T.E. Jr, Bartelson B.B. et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168: 538–542.

32. du Bois R.M., Weycker D., Albera C. et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am. J. Respir. Crit. Care Med. 2011; 184: 1382–1389.

33. Nathan S.D., du Bois R.M., Albera C. et al. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Respir. Med. 2015; 109: 914–922.

34. Nicholson A.G. Interstitial pneumonias. In: Cagle P.T., Fraire A.E., Tomashefski J.F. Jr., Farver C.F., eds. Dail and Hammar's Pulmonary Pathology. Springer Science + Business Media, LLC; 2008: 695–721.

35. Agarwal R., Jindal S.K. Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur. J. Intern. Med. 2008; 19: 227–235.

36. Gross T.J., Hunninghake G.W. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 2001; 345: 517–525.

37. King T.E., Tooze J.A., Schwarz M.I. et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am. J. Respir. Crit. Care Med. 2001; 164: 1171–1181.

38. Kim D.S., Collard H.R., King T.E. Classification and natural history of the idiopathic interstitial pneumonias. Proc. Am. Thorac. Soc. 2006; 3: 285–292.

39. Collard H.R., Ryerson C.J., Corte T.J. et al. Acute exacerbations of idiopathic pulmonary fibrosis. An International Working Group Report. Am. J. Respir. Crit. Care Med. 2016; 194: 265–275.

40. Akira M., Hamada H., Sakatani M. et al. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. Am. J. Roentgenol. 1997; 168: 79–83.

41. Ambrosini V., Cancellieri A., Chilosi M. et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur. Respir. J. 2003; 22: 821–826.

42. Konishi K., Gibson K.F., Lindell K.O. et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009; 180: 167–175.

43. Kim D.S., Park J.H., Park B.K. et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur. Respir. J. 2006; 27: 143–150.

44. Kondoh Y., Taniguchi H., Kitaichi M. et al. Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir. Med. 2006; 100: 1753–1759.

45. Hiwatari N., Shimura S., Takishima T., Shirato K. Bronchoalveolar lavage as a possible cause of acute exacerbation in idiopathic pulmonary fibrosis patients. Tohoku J. Exp. Med. 1994; 174: 379–386.

46. Parambil J.G., Myers J.L., Ryu J.H. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest. 2005; 128: 3310–3315.

47. Cottin V., Nunes H., Brillet P.Y. et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur. Respir. J. 2005; 26: 586–593.

48. Stahel R.A., Gilks W.R., Lehmann H.P., Schenker T. Third International Workshop on Lung Tumor and Differentiation Antigens: overview of the results of the central data analysis. Int. J. Cancer. Suppl. 1994; 8: 6–26.

49. Kohno N., Kyoizumi S., Awaya Y. et al. New serum indicator of interstitial pneumonitis activity: sialylated carbohydrate antigen KL-6. Chest. 1989; 96: 68–73.

50. Avdeeva O.E., Lebedin Yu.S., Avdeev S.N. et al. Glycosylated mucin antigen 3EG5 is a serum marker of activity and severity of interstitial lung disease. Pul'monologiya. 1998; 2: 22–27 (in Russian).

51. Greene K.E., King T.E. Jr, Kuroki Y. et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur. Respir. J. 2002; 19: 439–446.

52. Shinoda H., Tasaka S., Fujishima S. et al. Elevated CC chemokine level in bronchoalveolar lavage fluid is predictive of a poor outcome of idiopathic pulmonary fibrosis. Respiration. 2009; 78: 285–292.

53. Leuchte H.H., Baumgartner R.A., Nounou M.E. et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am. J. Respir. Crit. Care Med. 2006; 173: 744–750.

54. Rosas I.O., Richards T.J., Konishi K. et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008; 5: e93.

55. Phelps D.S., Umstead T.M., Mejia M. et al. Increased surfactant protein-A levels in patients with newly diagnosed idiopathic pulmonary fibrosis. Chest. 2004; 125: 617–625.

56. McCormack F.X., King T.E. Jr, Bucher B.L. et al. Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1995; 152: 751–759.

57. Moeller A., Gilpin S.E., Ask K. et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009; 179: 588–594.

58. Davies H.R., Richeldi L., Walters E.H. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 2003; (3): CD003134.

59. Richeldi L., Davies H.R., Ferrara G., Franco F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 2003; (3): CD002880.

60. Gay S.E., Kazerooni E.A., Toews G.B. et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am. J. Respir. Crit. Care Med. 1998; 157: 1063–1072.

61. Flaherty K.R., Toews G.B., Lynch J.P. III et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am. J. Med. 2001; 110: 278–282.

62. Demedts M., Behr J., Buhl R. et al. IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353 (21): 2229–2242.

63. Oldham J.M., Ma S.-F., Martinez F.J. et al. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2015; 192: 1475–1482.

64. Raghu G., Anstrom K.J., King T.E. Jr et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012; 366: 1968–1977.

65. Richeldi L., Costabel U., Selman M. et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2011; 365: 1079–1087.

66. Richeldi L., du Bois R.M., Raghu G. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2071–2082.

67. Oku H., Shimizu T., Kawabata T. et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur. J. Pharmacol. 2008; 590: 400–408.

68. King T.E. Jr, Bradford W.Z., Castro-Bernardini S. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2083–2092.

69. Douglas W.W., Ryu J.H., Schroeder D.R. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am. J. Respir. Crit. Care Med. 2000; 161: 1172–1178.

70. Morrison D.A., Stovall J.R. Increased exercise capacity in hypoxemic patients after long-term oxygen therapy. Chest. 1992; 102: 542–550.

71. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann. Intern. Med. 1980; 93: 391–398.

72. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema: report of the Medical Research Council Working Party. Lancet. 1981; 1: 681–686.

73. Mason D.P., Brizzio M.E., Alster J.M. et al. Lung transplantation for idiopathic pulmonary fibrosis. Ann. Thorac. Surg. 2007; 84: 1121–1128.

74. Keating D., Levvey B., Kotsimbos T. et al. Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years. Transplant. Proc. 2009; 41: 289–291.

75. Thabut G., Mal H., Castier Y. et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J. Thorac. Cardiovasc. Surg. 2003; 126: 469–475.

76. Egan J.J., Martinez F.J., Wells A.U., Williams T. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax. 2005; 60: 270–273.

77. Thabut G., Christie J.D., Ravaud P. et al. Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis. Ann. Intern. Med. 2009; 151: 767–774.

78. Stern J.B., Mal H., Groussard O. et al. Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure. Chest. 2001; 120: 213–219.

79. Al-Hameed F.M., Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. Can. Respir. J. 2004; 11: 117–122.

80. Mollica C., Paone G., Conti V. et al. Mechanical ventilation in patients with end-stage idiopathic pulmonary fibrosis. Respiration. 2010; 79: 209–215.

81. Mallick S. Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit. Respir. Med. 2008; 102: 1355–1359.

82. Holland A.E., Hill C.J., Conron M. et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. 2008; 63: 549–554.

83. Nishiyama O., Kondoh Y., Kimura T. et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology. 2008; 13: 394–399.

84. Ferreira A., Garvey C., Connors G.L. et al. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest. 2009; 135: 442–447.

85. Jastrzebski D., Gumola A., Gawlik R., Kozielski J. Dyspnea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation. J. Physiol. Pharmacol. 2006; 57: 139–148.

86. Naji N.A., Connor M.C., Donnelly S.C., McDonnell T.J. Effectiveness of pulmonary rehabilitation in restrictive lung disease. J. Cardiopulm. Rehabil. 2006; 26: 237–243.

87. Ghofrani H.A., Wiedemann R., Rose F. et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002; 360: 895–900.

88. Madden B.P., Allenby M., Loke T., Sheth A. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul. Pharmacol. 2006; 44: 372–376.

89. Collard H.R., Anstrom K.J., Schwarz M.I., Zisman D.A. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest. 2007; 131: 897–899.

90. Olschewski H., Ghofrani H.A., Walmrath D. et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am. J. Respir. Crit. Care Med. 1999; 160: 600–607.

91. Minai O.A., Sahoo D., Chapman J.T., Mehta A.C. Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease. Respir. Med. 2008; 102: 1015–1020.

92. Raghu G., Yang S.T., Spada C. et al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest. 2006; 129: 794–800.

93. Linden P.A., Gilbert R.J., Yeap B.Y. et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J. Thorac. Cardiovasc. Surg. 2006; 131: 438–446.

94. Lee J.S., Ryu J.H., Elicker B.M. et al. Gastroesophageal reflux therapy is associated with longer survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 184: 1390–1394.

95. Savarino E., Bazzica M., Zentilin P. et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am. J. Respir. Crit. Care Med. 2009; 179: 408–413.

96. Gulmez S.E., Holm A., Frederiksen H. et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch. Intern. Med. 2007; 167: 950–955.

97. Yang Y.X., Lewis J.D., Epstein S. et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006; 296: 2947–2953.

98. Collard H.R., King T.E. Jr, Bartelson B.B. et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168: 538–542.

99. King T.E. Jr, Safrin S., Starko K.M. et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest. 2005; 127: 171–177.

100. Zappala C.J., Latsi P.I., Nicholson A.G. et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010; 35: 830–836.

101. Raghu G., Brown K.K., Bradford W.Z. et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2004; 350: 125–133.

102. Azuma A., Nukiwa T., Tsuboi E. et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2005; 171: 1040–1047.

103. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 2002; 166: 111–117.